Cargando…

Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review

BACKGROUND: Asthma is a highly prevalent chronic inflammatory airways disease, with a considerable impact on quality of life (QoL). To express the effects of asthma on patients’ subjective experience, patient-reported outcomes (PROs) represent an important instrument. The asthma QoL questionnaire (A...

Descripción completa

Detalles Bibliográficos
Autores principales: Colombo, Giorgio Lorenzo, Di Matteo, Sergio, Martinotti, Chiara, Oselin, Martina, Valentino, Maria Chiara, Bruno, Giacomo Matteo, Pitotti, Claudia, Menzella, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492364/
https://www.ncbi.nlm.nih.gov/pubmed/31035904
http://dx.doi.org/10.1177/1753466619841350
_version_ 1783415129784713216
author Colombo, Giorgio Lorenzo
Di Matteo, Sergio
Martinotti, Chiara
Oselin, Martina
Valentino, Maria Chiara
Bruno, Giacomo Matteo
Pitotti, Claudia
Menzella, Francesco
author_facet Colombo, Giorgio Lorenzo
Di Matteo, Sergio
Martinotti, Chiara
Oselin, Martina
Valentino, Maria Chiara
Bruno, Giacomo Matteo
Pitotti, Claudia
Menzella, Francesco
author_sort Colombo, Giorgio Lorenzo
collection PubMed
description BACKGROUND: Asthma is a highly prevalent chronic inflammatory airways disease, with a considerable impact on quality of life (QoL). To express the effects of asthma on patients’ subjective experience, patient-reported outcomes (PROs) represent an important instrument. The asthma QoL questionnaire (AQLQ) is one of the main PROs among these. MATERIALS AND METHODS: To identify long-term asthma-related QoL outcomes associated with omalizumab therapy in patients with moderate-to-severe asthma, we developed a systematic review according to the PRISMA guidelines. Published real-world effectiveness studies of adults or adolescents (12 years or older) with moderate-to-severe allergic asthma treated with omalizumab for at least 48 weeks were reviewed. Sources used were Medline (PubMed), the Cochrane Library and Google Scholar up to February 2018. In addition, a cross-referencing search was conducted to complete the revision. RESULTS: A total of 255 potential papers were identified in the first search through the database. After full-text viewing, eight articles were finally included in the review. We summarized the results according to the study design, patient baseline characteristics and effectiveness outcomes assessed by AQLQ score results: variation from baseline to the end of study. Results confirmed the long-term benefits of omalizumab as an add-on therapy in patients with uncontrolled moderate-to-severe allergic asthma. Since there is a lot of evidence on omalizumab effectiveness, we aimed to focus on how a therapy can change patient’s QoL in a long time period. Data showed long-term effects of omalizumab treatment on subjective (PROs) and objective (lung function, corticosteroid use, hospitalizations, asthma exacerbation) effectiveness measures. CONCLUSION: Studies included in our review were observational trials that, due to their design, present a potential risk of selection bias in the patients included. Beyond this limit, the evaluation of QoL using the AQLQ showed a clear increase over time, following both 48 weeks and 9 years of observation, where QoL improvements still were significant over baseline values.
format Online
Article
Text
id pubmed-6492364
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-64923642019-05-08 Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review Colombo, Giorgio Lorenzo Di Matteo, Sergio Martinotti, Chiara Oselin, Martina Valentino, Maria Chiara Bruno, Giacomo Matteo Pitotti, Claudia Menzella, Francesco Ther Adv Respir Dis Systematic Review BACKGROUND: Asthma is a highly prevalent chronic inflammatory airways disease, with a considerable impact on quality of life (QoL). To express the effects of asthma on patients’ subjective experience, patient-reported outcomes (PROs) represent an important instrument. The asthma QoL questionnaire (AQLQ) is one of the main PROs among these. MATERIALS AND METHODS: To identify long-term asthma-related QoL outcomes associated with omalizumab therapy in patients with moderate-to-severe asthma, we developed a systematic review according to the PRISMA guidelines. Published real-world effectiveness studies of adults or adolescents (12 years or older) with moderate-to-severe allergic asthma treated with omalizumab for at least 48 weeks were reviewed. Sources used were Medline (PubMed), the Cochrane Library and Google Scholar up to February 2018. In addition, a cross-referencing search was conducted to complete the revision. RESULTS: A total of 255 potential papers were identified in the first search through the database. After full-text viewing, eight articles were finally included in the review. We summarized the results according to the study design, patient baseline characteristics and effectiveness outcomes assessed by AQLQ score results: variation from baseline to the end of study. Results confirmed the long-term benefits of omalizumab as an add-on therapy in patients with uncontrolled moderate-to-severe allergic asthma. Since there is a lot of evidence on omalizumab effectiveness, we aimed to focus on how a therapy can change patient’s QoL in a long time period. Data showed long-term effects of omalizumab treatment on subjective (PROs) and objective (lung function, corticosteroid use, hospitalizations, asthma exacerbation) effectiveness measures. CONCLUSION: Studies included in our review were observational trials that, due to their design, present a potential risk of selection bias in the patients included. Beyond this limit, the evaluation of QoL using the AQLQ showed a clear increase over time, following both 48 weeks and 9 years of observation, where QoL improvements still were significant over baseline values. SAGE Publications 2019-04-29 /pmc/articles/PMC6492364/ /pubmed/31035904 http://dx.doi.org/10.1177/1753466619841350 Text en © The Author(s), 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Systematic Review
Colombo, Giorgio Lorenzo
Di Matteo, Sergio
Martinotti, Chiara
Oselin, Martina
Valentino, Maria Chiara
Bruno, Giacomo Matteo
Pitotti, Claudia
Menzella, Francesco
Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review
title Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review
title_full Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review
title_fullStr Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review
title_full_unstemmed Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review
title_short Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review
title_sort omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492364/
https://www.ncbi.nlm.nih.gov/pubmed/31035904
http://dx.doi.org/10.1177/1753466619841350
work_keys_str_mv AT colombogiorgiolorenzo omalizumabandlongtermqualityoflifeoutcomesinpatientswithmoderatetosevereallergicasthmaasystematicreview
AT dimatteosergio omalizumabandlongtermqualityoflifeoutcomesinpatientswithmoderatetosevereallergicasthmaasystematicreview
AT martinottichiara omalizumabandlongtermqualityoflifeoutcomesinpatientswithmoderatetosevereallergicasthmaasystematicreview
AT oselinmartina omalizumabandlongtermqualityoflifeoutcomesinpatientswithmoderatetosevereallergicasthmaasystematicreview
AT valentinomariachiara omalizumabandlongtermqualityoflifeoutcomesinpatientswithmoderatetosevereallergicasthmaasystematicreview
AT brunogiacomomatteo omalizumabandlongtermqualityoflifeoutcomesinpatientswithmoderatetosevereallergicasthmaasystematicreview
AT pitotticlaudia omalizumabandlongtermqualityoflifeoutcomesinpatientswithmoderatetosevereallergicasthmaasystematicreview
AT menzellafrancesco omalizumabandlongtermqualityoflifeoutcomesinpatientswithmoderatetosevereallergicasthmaasystematicreview